Agios To Present at September Investor Conferences
- Citi’s 16th Annual Biopharma Virtual Conference
Panel: Sickle Cell, Beta-Thal, ITP & PKD - Measuring Industry Progress in Benign Hematology
Friday, September 10at 12:30 p.m. ET
Cantor Virtual Global HealthcareConference Monday, September 27at 8:00 a.m. ET
Live webcasts of the presentations can be accessed under “Events & Presentations” in the Investors section of the company's website at www.agios.com. Replays of the webcasts will be archived on the Agios website for at least two weeks following each presentation.
Agios is focused on discovering and developing novel investigational medicines to treat genetically defined diseases through scientific leadership in the field of cellular metabolism. The company’s most advanced drug candidate is a first-in-class pyruvate kinase R (PKR) activator, mitapivat, that is currently being evaluated for the treatment of three distinct hemolytic anemias. In addition to its active late-stage clinical pipeline, Agios has multiple novel, investigational therapies in clinical and preclinical development. For more information, please visit the company’s website at www.agios.com.
Director, Corporate Communications
Source: Agios Pharmaceuticals, Inc.